Celgene wins Chinese regulatory OK for Revlimid

Mon Feb 11, 2013 7:35pm IST

Related Topics

Stocks

   

(Reuters) - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.

Multiple myeloma is the second most commonly diagnosed blood cancer. There are an estimated 750,000 people with the disease worldwide, according to the International Myeloma Foundation.

Celgene said it expects the drug to be available to Chinese patients late in the second quarter of 2013.

In addition, the biotechnology company said Revlimid, or lenalidomide, was granted priority review by the U.S. Food and Drug Administration as a treatment for patients with relapsed or refractory mantle cell lymphoma.

Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy, in almost 70 countries, including the Americas and Europe.

It is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia.

(Reporting By Debra Sherman; Editing by Gerald E. McCormick)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Bullying Impact

Reuters Showcase

A Little Help

A Little Help

Researchers "buzz" the brain to speed up learning.  Video 

Disease Outbreak

Disease Outbreak

WHO says West African Ebola outbreak to last 2-4 months.  Full Article 

Healthy Food

Healthy Food

For teen girls, fruits and veggies linked to lower risk of breast condition.  Full Article 

Milk Effect

Milk Effect

Drinking milk may slow women's knee arthritis.  Full Article 

Rising Obesity

Rising Obesity

U.S. childhood obesity rates have increased since 1999: study.  Full Article 

Quality Check

Quality Check

Just because it's sweet and sticky doesn't mean it's 'honey': FDA.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.   Full Coverage